182 related articles for article (PubMed ID: 34041642)
21. Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study.
Kantor ED; Lipworth L; Fowke JH; Giovannucci EL; Mucci LA; Signorello LB
Prostate; 2015 Sep; 75(13):1384-93. PubMed ID: 26012482
[TBL] [Abstract][Full Text] [Related]
22. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.
Anderson-Carter I; Posielski N; Liou JI; Khemees TA; Downs TM; Abel EJ; Jarrard DF; Richards KA
Urol Oncol; 2019 Feb; 37(2):130-137. PubMed ID: 30528885
[TBL] [Abstract][Full Text] [Related]
23. Associations among statins, preventive care, and prostate cancer mortality.
Kumar A; Riviere P; Luterstein E; Nalawade V; Vitzthum L; Sarkar RR; Bryant AK; Einck JP; Mundt AJ; Murphy JD; Rose BS
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):475-485. PubMed ID: 32029930
[TBL] [Abstract][Full Text] [Related]
24. Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.
Mikkelsen MK; Thomsen FB; Berg KD; Jarden M; Larsen SB; Hansen RB; Brasso K
Scand J Urol; 2017 Dec; 51(6):464-469. PubMed ID: 28831860
[TBL] [Abstract][Full Text] [Related]
25. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
26. Testosterone therapy in prostate cancer: is it still a controversy?
Bart AS; Van Hoof A; Badre-Hume R; Selvarajah J; Robillard K; Albala DM
Curr Opin Urol; 2022 Nov; 32(6):598-606. PubMed ID: 36081393
[TBL] [Abstract][Full Text] [Related]
27. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.
Beebe-Dimmer JL; Ruterbusch JJ; Cooney KA; Bolton A; Schwartz K; Schwartz AG; Heath E
Cancer Med; 2019 Jun; 8(6):3325-3335. PubMed ID: 31094098
[TBL] [Abstract][Full Text] [Related]
28. Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997-2010.
Jespersen CG; Nørgaard M; Friis S; Skriver C; Borre M
Cancer Epidemiol; 2014 Feb; 38(1):42-7. PubMed ID: 24275259
[TBL] [Abstract][Full Text] [Related]
29. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.
Chao C; Jacobsen SJ; Xu L; Wallner LP; Porter KR; Williams SG
BJU Int; 2013 May; 111(6):954-62. PubMed ID: 23464862
[TBL] [Abstract][Full Text] [Related]
30. Statin drugs and risk of advanced prostate cancer.
Platz EA; Leitzmann MF; Visvanathan K; Rimm EB; Stampfer MJ; Willett WC; Giovannucci E
J Natl Cancer Inst; 2006 Dec; 98(24):1819-25. PubMed ID: 17179483
[TBL] [Abstract][Full Text] [Related]
31. Endogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk?
Lopez DS; Advani S; Tsilidis KK; Wang R; Canfield S
Transl Androl Urol; 2017 Jun; 6(3):566-579. PubMed ID: 28725600
[TBL] [Abstract][Full Text] [Related]
32. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients.
Lehman DM; Lorenzo C; Hernandez J; Wang CP
Diabetes Care; 2012 May; 35(5):1002-7. PubMed ID: 22456867
[TBL] [Abstract][Full Text] [Related]
33. Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men: a population-based study.
Chinea FM; Patel VN; Kwon D; Lamichhane N; Lopez C; Punnen S; Kobetz EN; Abramowitz MC; Pollack A
Oncotarget; 2017 Sep; 8(41):69709-69721. PubMed ID: 29050235
[TBL] [Abstract][Full Text] [Related]
34. Racial/Ethnic Disparities in Prostate Cancer Incidence, Distant Stage Diagnosis, and Mortality by U.S. Census Region and Age Group, 2012-2015.
Iyengar S; Hall IJ; Sabatino SA
Cancer Epidemiol Biomarkers Prev; 2020 Jul; 29(7):1357-1364. PubMed ID: 32303533
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial.
Murtola TJ; Tammela TL; Määttänen L; Huhtala H; Platz EA; Ala-Opas M; Stenman UH; Auvinen A
Int J Cancer; 2010 Oct; 127(7):1650-9. PubMed ID: 20073066
[TBL] [Abstract][Full Text] [Related]
36. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Allott EH; Howard LE; Cooperberg MR; Kane CJ; Aronson WJ; Terris MK; Amling CL; Freedland SJ
BJU Int; 2014 Nov; 114(5):661-6. PubMed ID: 24588774
[TBL] [Abstract][Full Text] [Related]
37. Association of race/ethnicity and patient care experiences with receipt of definitive treatment among prostate cancer survivors: a SEER-CAHPS study.
Pandit AA; Halpern MT; Gressler LE; Kamel M; Payakachat N; Li C
Cancer Causes Control; 2024 Apr; 35(4):647-659. PubMed ID: 38001335
[TBL] [Abstract][Full Text] [Related]
38. Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness.
Morote J; Celma A; Planas J; Placer J; de Torres I; Olivan M; Carles J; Reventós J; Doll A
Int J Mol Sci; 2014 Aug; 15(8):13615-23. PubMed ID: 25101846
[TBL] [Abstract][Full Text] [Related]
39. Controversies in Testosterone Therapy.
Twitchell DK; Pastuszak AW; Khera M
Sex Med Rev; 2021 Jan; 9(1):149-159. PubMed ID: 33309270
[TBL] [Abstract][Full Text] [Related]
40. Exposure to statins post localized prostate cancer diagnosis and risk of metastasis among men who did not receive curative prostate cancer treatment.
Habeshian TS; Shu YH; Cannavale KL; Slezak JM; Chien GW; Vandeneeden SK; Chao CR
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1749. PubMed ID: 36349511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
